Yuekang Pharmaceutical Co., Ltd. (688658.SH) subsidiary YKYY013 injection has obtained FDA clinical trial approval.

Wisdom Financial APP News, YK Pharmaceutical (688658.SH) announced that its subsidiary Beijing YK Science and Technology Pharmaceutical Co., Ltd. (referred to as "YK Science and Technology") recently received a letter from the Food and Drug Administration (FDA) of the United States approving YKYY013 injection for the treatment of chronic hepatitis B virus infection to proceed with clinical trials (Study May Proceed Letter, IND number: 177486).